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Background: Data on plasma acylated ghrelin (AG) and unacylated ghrelin (UAG) levels in acro-
megaly are limited. High AG/UAG ratios are linked with type 2 diabetes, obesity, and hyperphagia
(e.g., in Prader-Willi syndrome).
Objective: To assess fasting plasmaAGandUAG levels, and theAG/UAG ratio in acromegaly patients
receiving combination treatment of long-acting somatostatin analogs (LA-SSAs) and pegvisomant
(PEGV; n = 60). We used as controls acromegaly patients whose disease was controlled with PEGV
monotherapy and medically naı¨ve patients with active acromegaly.
Methods: Fasting venous blood samples were collected and directly stabilized to inhibit deacylation
of AG. Plasma AG and UAG levels were determined by double-antibody sandwich enzyme
immunoassay, and the AG/UAG ratio was calculated.
Results: Plasma AG and UAG levels were significantly lower in patients with acromegaly receiving
combination treatment [median, interquartile range (IQR): AG: 8.5 pg/mL, 2.9 to 21.1 pg/mL; UAG:
26.9 pg/mL, 11.2 to 42.1 pg/mL] comparedwith patients using PEGV alone [AG: 60.5 pg/mL (IQR, 58.8
to 77.4 pg/mL); UAG: 153.7 pg/mL (IQR, 127.3 to 196.0 pg/mL)] and medically naı¨ve patients with
acromegaly [AG: 24.0 pg/mL (IQR, 12.6 to 49.7 pg/mL); UAG: 56.3 pg/mL (IQR, 43.4 to 61.5 pg/mL)].
However, AG/UAG ratios were similar in all groups.
Conclusions: Although plasma AG and UAG are suppressed during combination treatment with LA-
SSAs and PEGV, theAG/UAG ratio remained similar. This shows that SSAs decrease bothAG andUAG
levels, which suggests that they do not alter metabolism significantly in acromegaly patients. (J Clin
Endocrinol Metab 102: 2425–2432, 2017)
Ghrelin is a small peptide hormone secreted mainly byneuroendocrine X/A cells in the stomach (1, 2). In
the circulation, it consists of two isoforms: acylated
ghrelin (AG) and unacylated ghrelin (UAG). Both
isoforms are detectable in equal amounts in the cir-
culation (3). AG differs from UAG in being acylated by
attachment of a medium-chain fatty acid at its serine-3
residue. AG is acylated by the intracellular enzyme
ghrelin O-acyl transferase and is responsible for the
distinct metabolic and nonmetabolic effects of ghrelin
in vivo (4–11). AG acts on the hypothalamus through
the growth hormone secretagogue receptor (GHSR1a)
and is known to be diabetogenic, orexigenic, and obeso-
genic. UAG does not bind to the GHSR1a receptor at
physiological concentrations and, therefore, was con-
sidered to be inactive.However, recent studies have shown
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linked immunosorbent assay; GH, growth hormone; GHSR1a, growth hormone
secretagogue receptor; HbA1c, glycated hemoglobin; HOMA-IR, homeostasis model
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that UAG is able to counteract the metabolic effects of
AG (9, 12).
Because AG and UAG have distinct biological effects
and can affect each other, the AG/UAG ratio may be a
more important parameter than individual levels of AG
and UAG (13–19). For example, elevated AG/UAG
ratios have been associated with diabetes, obesity, and
hyperphagia (13, 20–25). Hyperphagia is a hallmark of
Prader-Willi syndrome, a rare cause of genetic, early-onset
obesity, which is characterized by elevated total ghrelin
levels but changing AG/UAG ratios throughout life
(20, 22, 26).
It is known that ghrelin stimulates growth hormone
(GH) secretion, whereas ghrelin itself is reduced after GH
infusion (11, 27–29). However, the exact physiological
role of ghrelin in the regulation of GH release is not
entirely established (30–33).
In acromegaly, a prototype disease characterized by
excessive GH levels, the emerging picture from previous
studies is that, in medically naı¨ve patients during active
disease, total ghrelin levels are lowered comparedwith levels
in control subjects (27, 34, 35). Ghrelin levels are elevated
after surgery, whereas they are reduced during treatment
with long-acting somatostatin analogs (LA-SSAs) (34–37).
Patients with acromegaly treated with the competitive
GH receptor blocker pegvisomant (PEGV) have higher total
ghrelin levels than patients with active disease (38).
However, to our knowledge, the effect of combination
treatment with long-acting somatostatin analogs (LA-SSAs)
and PEGV on plasma AG and UAG levels in acromegaly
remains unknown. Similarly, AG and UAG levels have not
been assessed together in patients with acromegaly.
Therefore, the aim of this study was to assess fasting
plasmaAG andUAG levels and to determine the AG/UAG
ratio in patients with acromegaly who were receiving
combination treatment with somatostatin analogs and
PEGV (n = 60), and compare them with the ratios in
patients receiving PEGV monotherapy (n = 4) and in
medically naı¨ve patients with acromegaly (n = 5).
Patients and Methods
Study design
We prospectively recruited 69 patients with acromegaly at
our outpatient clinic at the Erasmus University Medical Center,
Rotterdam, The Netherlands, between August 2015 and June
2016. For most of these patients, their acromegaly was bio-
chemically controlled in the long termwith combination treatment
of LA-SSAs and PEGV (n = 60), four patients were treated with
PEGV monotherapy, and five patients were medically naı¨ve
with active acromegaly. We excluded patients with eating
disorders, active malignancies, active inflammatory or infec-
tious diseases, epilepsy, and psychiatric disorders. Patients
with acromegaly were considered diabetic either if they were
taking antidiabetic medication or had a history of diabetes
mellitus, or had glycated hemoglobin (HbA1c) levels $6.5%.
In addition to measurement of plasma AG and UAG, we
assessed in the fasting state: glucose, insulin, HbA1c, insulinlike
growth factor 1 (IGF1), and GH levels. The patients’ body
weight and height also were measured. Serum glucose, insulin,
and HbA1c values were determined with standard laboratory
methods. The updated homeostasis model assessment was used
to assess insulin resistance (HOMA-IR) and b-cell function
from pairs of fasting glucose and insulin levels.
All patients gave theirwritten informed consent, and the study
was approved by the Medical Ethics Committee of Erasmus
University MC, Rotterdam.
Materials
Vacutainers were obtained from Becton Dickinson (6 mL
of di-potassium EDTA; catalog no. 367899; Breda,
The Netherlands); 4-(2-aminoethyl) benzenesulphonyl
fluoride hydrochloride [(AEBSF) Pefabloc SC; Sigma-
Aldrich, St. Louis,MO]was purchased fromRocheApplied
Science (catalog no. 11429876001; Almere, The Nether-
lands). Stock solutions of 200 mg/mL AEBSF in distilled
water were prepared (39, 40).
HumanAG andUAG levels were determined by double-
antibody sandwich enzyme immunoassay kits obtained
from Bertin Pharma (catalog nos. A05106 and A05119,
respectively; Montigny-le-Bretonneux, France) (39).
Total IGF1 concentrations were measured by chemi-
luminescent immunometric assay (IDS-iSYS; Immunodi-
agnostic Systems, Boldon, United Kingdom) and were
interpreted according to the sex-dependent and age-
dependent ranges. GH levels were measured using the
IDS-iSYS assay, which is free of interference from
PEGV (41).
Blood collection, AEBSF treatment, and storage
Overnight-fasting venous blood samples for the mea-
surement of plasmaAG and plasma UAGwere drawn and
collected inEDTAtubes.One 4-mLEDTA tubeper patient
was collected. AEBSF was immediately added to all blood
samples (1:100 dilution; final concentration, 2 mg/mL) to
prevent deacylation of AG to UAG (39, 42). Whole blood
was mixed gently by inversion (three times) and stored on
water ice (4°C) until centrifugation at 2500g at 4°C for
5 minutes. Plasma of these venous blood samples was then
rapidly aliquoted in four 1.5-mL Eppendorf tubes (300mL
in each). All plasma samples were stored at 280°C until
the assay was performed. AEBSF was stored for a maxi-
mum of 1 month after dilution.
Acylated and unacylated ghrelin enzyme-linked
immunosorbent assays
After thawing on ice, plasma samples were centrifuged
for 1 minute at 1500g and 4°C, and kept on ice before
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transferring to the assay plates. All samples were mea-
sured in duplicate (50 mL/well), according to the man-
ufacturer’s protocol (39).
A sigmoidal third-order cubic polynomial fitting was
used to determine concentrations from the calibration
curves. This resulted in r2 values .0.99 in most of the
assays. For the Bertin Pharma EIAs, the average intra-
assay percent coefficient of variation (%CV) was 2.1 for
AG and 4.6 for UAG. The average interassay %CV was
9.5 for AG and 12.8 for UAG. The %CVs were assessed
over six assays. The lower limit of detection was 4 pg/mL.
Statistical analysis
Analyses were performed using SPSS software (version
24 for Windows; SPSS Inc., Chicago, IL) and GraphPad
Prism® version 6.04 (GraphPad Software, San Diego,
CA). The Kolmogorov-Smirnov test was used to test
normality of variables (data were considered to be nor-
mally distributed when P . 0.05). Comparisons across
all groups were analyzed with the Kruskall-Wallis test.
Comparisons between patient groups were analyzed by
Wilcoxon signed-ranks tests and Mann-Whitney U tests.
Correlation analyses were done using the Spearman
rank-correlation test. Data were reported as median
[interquartile range (IQR)] because they were not
normally distributed. P , 0.05 was considered sta-
tistically significant.
Results
Clinical characteristics
Table 1 shows the patients’ demographics, charac-
teristics, and disease history. Plasma AG and UAG levels
were measured in a total of 69 acromegaly patients. One-
third of patients (20 of 60) who received combination
treatment had previously undergone surgery, whereas 7
of 60 patients had undergone surgery and radiotherapy in
the past. In patients receiving PEGVmonotherapy, two of
four patients had undergone both surgery and radio-
therapy. In medically naı¨ve patients with active disease,
two of five patients had previously undergone surgery.
Clinical characteristics were comparable among the groups
with respect to age, sex, body mass index, and previous
therapy. Patients receiving combination treatment with
LA-SSAs and PEGV and patients receiving PEGV mon-
otherapy had IGF1 levels within the age- and sex-adjusted
normal limits.
Figure 1 shows the median fasting levels of AG and
UAG, and the AG/UAG ratio. Levels of AG and UAG
were significantly different between the groups (Kruskal-
Wallis test: AG, P = 0.004; UAG, P = 0.005).
Median (IQR) AG levels were significantly lower in
patients using combination treatment compared with
patients using PEGV monotherapy and with medically
naı¨ve patients [respective Mann-Whitney U test re-
sults: 8.5 pg/mL (2.9 to 21.1 pg/mL) vs 60.5 pg/mL
(58.8 to 77.4 pg/mL), P = 0.0002; vs 24.0 pg/mL (12.6
to 49.7 pg/mL), P = 0.03]. There was no significant
difference in AG between patients using PEGV and the
medically naı¨ve patients (Wilcoxon signed-rank test:
P = 0.25).
Although UAG levels were higher than AG levels in all
groups, they showeda similar pattern.Median (IQR)UAG
levels were significantly lower during combination treat-
ment compared with the other groups (respective Mann-
Whitney U test results: [26.9 pg/mL (11.2 to 42.1 pg/mL)
Table 1. Characteristics of All Patients in the Three Study Groups
Parameters LA-SSA + PEGV PEGV Medically Naı¨ve Acromegaly
No. of patients 60 4 5
Male sex, no. (%) 32 (53) 2 (50) 2 (40)
Age, mean (range), y 54 (27–81) 62 (44–82) 44 (29–62)
BMI, kg/m2 28.8 (26.0–31.7) 30.9 (24.1–34.9) 30.3 (26.1–35.4)
Previous therapy, no. (%)
Surgery 20 (33) 0 2 (40)
Radiotherapy 0 0 0
Surgery and radiotherapy 7 (11.7) 2 (50) 0
IGF1, nmol/L 25.7 (22.2–32.3) 27.0 (22.4–36.0) 96.1 (64.0–166.0)
IGF1 3 ULN 0.99 (0.85–1.12) 1.09 (0.90–1.28) 3.63 (2.20–4.50)
GH, mg/L 4.6 (1.7–8.6) 3.1 (0.7–17.6) 15.4 (11.7–112.0)
Fasting glucose, mmol/L 6.1 (5.6–6.8) 4.6 (4.3–4.9) 5.5 (5.1–6.2)
HbA1c, % 5.9 (5.7–6.2) 5.6 (5.5–5.9) 5.6 (5.3–6.4)
Diabetes mellitus, no. (%) 14 (23) 0 (0) 1 (20)
HOMA-IR score 1.1 (0.7–1.5) NA NA
HOMA b-cell score 67.2 (49.3–90.5) NA NA
PEGV dose, mg/wk 100 (60–160) 175 (95–289) —
Data are expressed as median and IQR, unless otherwise specified.
Abbreviations: —, not applicable; BMI, body mass index; NA, not available; ULN, upper limit of normal.
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vs 127.3 pg/mL (153.7 to 196.0 pg/mL), P = 0.0002; vs
56.3 pg/mL (43.3 to 61.5 pg/mL), P = 0.03])]. Similar to
AG, UAG levels were not different between patients using
PEGV and medically naı¨ve patients (Wilcoxon signed-
rank test: P = 0.13).
AG/UAG ratios were not significantly different be-
tween the groups (P = 0.65). The median (IQR) AG/UAG
ratio was 0.38 (0.16 to 0.59) in the combination group vs
0.40 (0.31 to 0.60) in the PEGV monotherapy group vs
0.53 (0.24 to 0.90) in medically naı¨ve patients.
The highest AG level of 140.6 pg/mLwas observed in a
55-year-old man with long-term controlled acromegaly
treated with lanreotide Autogel (Ipsen, Paris, France)
120 mg every 4 weeks and PEGV 100 mg/wk. At the time
of the blood sampling, this patient had an IGF1 level
of 1.17 times the upper limit of normal. His type 2
diabetes (HbA1c, 6.9%) was well regulated with met-
formin and he received testosterone replacement because
of hypogonadism.
In another patient, we observed the second highest AG
level of 117.1 pg/mL and the highest observed UAG level
of 177.5 pg/mL. This was a 27-year-old patient with
acromegaly who had undergone a transsphenoidal hy-
pophysectomy twice. At the time of the blood sampling,
her condition was controlled with octreotide long-acting
release every 4 weeks and PEGV 80 mg/wk.
Concentrations of plasma AG [Fig. 1(a)] and UAG
[Fig. 1(b)] were very low in the LA-SSA and PEGV
combination treatment group. In 17 patients (28%) re-
ceiving combination treatment, AG levels were unde-
tectable, whereas in four patients (6.7%), UAG levels
were undetectable.
We found no statistically significant relationship
between plasma AG, UAG, and AG/UAG ratios vs
biochemical parameters [i.e., GH, IGF1, HbA1c levels,
HOMA-IR score, HOMA b-cell score, and clinical
parameters (age, sex, body mass index, diabetes, pre-
vious surgery, previous radiotherapy, PEGV dose)]
among the groups of patients with acromegaly. Al-
though not statistically significant, a negative correla-
tion (r = 20.25; P = 0.06) was observed between
previous surgery and UAG levels in patients receiving
combination treatment.
Discussion
Our main finding was that the AG/UAG ratio was not
altered in patients with acromegaly during different
treatment regimens. AG and UAG levels were suppressed
during combination treatment with LA-SSAs and PEGV,
compared with patients using PEGV alone and with
medically naı¨ve active acromegaly. This is in line with
literature on total ghrelin levels, although previous
studies lacked information on the ratios between AG/
UAG. It is questionable whether higher single AG and
UAG levels have a physiological role during PEGV
Figure 1. In patients with acromegaly who were treated with
combination therapy consisting of LA-SSAs and PEGV (n = 60),
patients with acromegaly receiving PEGV monotherapy (n = 5), and
medically naı¨ve patients with acromegaly (n = 4), (a) plasma AG, (b)
plasma UAG, and (c) AG/UAG ratios are depicted. Data are
expressed as median 6 IQR. (a, b) *P , 0.05; **P , 0.001.
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treatment and active disease if the ratios remain the same.
Therefore, assessment of total ghrelin assessment is
probably not clinically useful.
TheAG/UAG ratio is probablymore clinically relevant
than measurement of total ghrelin. The main problem
with previous studies examining ghrelin levels in patients
with acromegaly is the small number of samples assessed
and the use of ghrelin assays that do not distinguish
between acylated and unacylated ghrelin. Commer-
cial radioimmunoassays (RIAs) and one-site competitive
enzyme-linked immunosorbent assays (ELISAs) measure
total human serum ghrelin by using labeled UAG as a
tracer and a polyclonal antibody against the C-terminal
end of human ghrelin. These assays overestimate ghrelin
levels because they measure peptide fragments as well as
full-length peptide. These fragments exist naturally in the
circulation and lack the N-terminal region, but can also
be artificially produced during the assay procedure. Two-
site ELISAs use antibodies directed against both ends of
the peptide and, therefore, are highly specific and will
only measure unfragmented ghrelin. Using their two-site
sandwich ELISA as a comparison, Akamizu et al. (43)
have demonstrated that about 40% to 60% of the total
ghrelin measured by RIA is likely fragmented. This was
further confirmed by Prudom et al. (44) who showed that
their two-site sandwich ELISAs for AG and UAG pro-
vided greater specificity. They found that dynamic
changes in AG were dampened and less visible in the
RIAs. AG has a short half-life and, in circulation, it is
rapidly degraded to UAG. For this reason, blocking
deacylation is crucial for reliable measurements of AG
and UAG (39, 42).
The observation of low AG and UAG levels during
combination treatment of LA-SSA and PEGV suggests
that this effect is caused by the SSAs. This finding is in
line with previous studies showing that LA-SSAs
suppress ghrelin levels in patients with acromegaly
(34, 36). Freda et al. (34) evaluated fasting and serum
ghrelin levels after an oral glucose tolerance test in
patients with active acromegaly at baseline and after
either surgery or administration of LA-SSAs. They
observed that fasting total ghrelin levels were higher in
patients after surgery, but these levels fell significantly
after treatment with LA-SSAs. The researchers sug-
gested that the postoperative lowering of insulin levels
and improved insulin sensitivity may have contributed
to the postoperative rise of ghrelin levels (34). Another
report also suggested that patients with acromegaly
with greater insulin resistance have lower total ghrelin
levels (27). Several studies have indicated that hyper-
insulinemia inhibits AG and UAG secretion; conversely,
AG itself inhibits insulin secretion (14, 45–47). However,
we could only assess insulin levels in the combination
group and, therefore, cannot draw any conclusions on the
difference in insulin sensitivity between the groups.
The observation of higher AG and UAG levels in
patients using PEGV suggests that PEGV itself can
stimulate AGandUAG.Roemmler et al. (38) showed that
acromegaly patients using PEGV had higher total ghrelin
levels compared with healthy control subjects, patients
with active acromegaly, and those with inactive acro-
megaly. This finding suggests that treatment with PEGV
might disrupt the feedback loop of ghrelin and GH,
leading to elevated ghrelin levels. The ghrelin receptor
GHSR1a is expressed in normal pituitary and somato-
troph adenomas (48). GH administration has been shown
to suppress total ghrelin levels in GH-deficient patients
(49). In rodents, GH administration in cultured stomach
tissue reduced total ghrelin secretion, whereas hypophy-
sectomy increased ghrelin levels (50–52). These results
support the notion that GH exerts a negative feedback
action on ghrelin secretion. Although there are no studies
evaluating the direct effect of PEGV on ghrelin secretion,
these data indirectly suggest that blockade of the GH
receptor with PEGV leads to a positive feedback action
on ghrelin secretion.
Inpatients using combination treatment,median plasma
AG levels were 8.5 pg/mL (range, 0 to 140.6 pg/mL)
and median UAG levels were 26.9 pg/mL (range, 0 to
177.5 pg/mL). This is considerably lower than levels that
have been observed in healthy control subjects, measured
using equivalent two-site sandwich assays and stabilized
withAEBSF.Adrichem et al. (40) foundmedian plasmaAG
levels of 57.2 pg/mL (range, 10 to 273 pg/mL) and median
plasma UAG levels of 64.9 pg/mL (range, 8 to 331 pg/mL)
in 28 healthy control subjects, whereas Liu et al. (53)
reported AG levels ranging from 43 to 366 pg/mL in four
healthy volunteers.
AG and UAG exert distinct effects on glucose ho-
meostasis and insulin sensitivity. AG has diabetogenic
actions; it induces insulin resistance and reduces insulin
secretion. However, UAG displays antidiabetogenic ac-
tions (13–19). UAG alone or in combination with AG
improves insulin sensitivity through the suppression of
AG levels in obese subjects with type 2 diabetes (9).
Studies have shown that insulin-resistant obese subjects
have an elevated AG/UAG ratio compared with insulin-
sensitive obese subjects (13, 24, 25), which can be
explained by a relative UAG deficiency in obese subjects
(23). Conversely, low AG/UAG ratios are associated with
an improved metabolic state (21).
Prader-Willi syndrome is characterized by distinct
nutritional phenotypes, from anorexia in infancy to hy-
perphagia and obesity in childhood (26). Recently, it
was revealed that although total hyperghrelinemia was
observed at all ages throughout life in Prader-Willi
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syndrome, the AG/UAG ratio changed over time, driving
opposite phenotypes. Although the AG/UAG ratio was
low during infancy, it switched to a high AG/UAG ratio
later in life (20, 22).
These data illustrate that AG and UAG have opposing
actions, and that the AG/UAG ratio yields more physi-
ological importance than measurement of absolute levels
of AG and UAG. Although our patients receiving com-
bination therapy had lower AG and UAG levels, the AG/
UAG ratio was similar between all groups. This suggests
that treatment with LA-SSAs and PEGVdoes not alter the
relation of AG with respect to UAG.
In summary, the plasma AG/UAG ratio was not al-
tered in patients with acromegaly during medical treat-
ment. Absolute levels of individual assessments of AG
and UAG, however, were lower than observed during the
assessment of total ghrelin levels. Assessment of the AG/
UAG ratio is more clinically relevant because it is a better
reflection of the physiological bioactive state of ghrelin
than measurement of total ghrelin. Therefore, we rec-
ommend assessment of AG and UAG separately and
calculation of the AG/UAG ratio.
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